Leukemia & Lymphoma Society of Canada
STAR RATINGCi's Star Rating is calculated based on the following independent metrics: |
✔+
FINANCIAL TRANSPARENCY
Audited financial statements for current and previous years available on the charity’s website.
B-
RESULTS REPORTING
Grade based on the charity's public reporting of the work it does and the results it achieves.
n/r
DEMONSTRATED IMPACT
The demonstrated impact per dollar Ci calculates from available program information.
NEED FOR FUNDING
Charity's cash and investments (funding reserves) relative to how much it spends on programs in most recent year.
56%
CENTS TO THE CAUSE
For a dollar donated, after overhead costs of fundraising and admin/management (excluding surplus) 56 cents are available for programs.
My anchor
OVERVIEW
About Leukemia & Lymphoma Society of Canada:
Leukemia & Lymphoma Society of Canada is a 3-star charity with a below average results reporting grade. It is financially transparent. Leukemia & Lymphoma Society's overhead costs are outside Ci's reasonable range.
Founded in 1955, Leukemia & Lymphoma Society of Canada (LLSC) supports those affected by blood cancer. The charity states there are currently 155,593 people living with or in remission from blood cancer. LLSC runs three major programs: Research, Patient Support and Public Education. Charity Intelligence calculates it spent $9.1m on its programs and grants in F2023.
The Research program received 49% of program spending. The charity states it will not stop until there is a cure for all types of blood cancer. In F2023 LLSC funded the work of 37 blood cancer researchers across Canada.
The Patient Support program received 29% of program spending. LLSC provides support for those affected by blood cancer, and their families. In F2023 it engaged 307 people in 52 mental health virtual support meetings. The charity financially supported 773 people for medical travel in the One Kilometer at a Time subprogram. The First Connection subprogram connects those with blood cancer to a blood cancer survivor. In F2023 there were 438 requests for peer matches.
The Public Education program received 22% of program spending. In F2023 1,700 people registered for a Causes of Blood Cancer webcast. The charity involved 7,319 people in blood cancer related educational events. The Public Education program includes educating healthcare professionals. In F2023 the charity trained 1,000 healthcare professionals through its education platform. LLSC hosted its first pediatric oncology day at the 2023 Oncology Conference.
My anchor
Results and Impact
Charity Intelligence did not find any quantified outcomes on Leukemia & Lymphoma Society of Canada's website. This may not be a complete representation of Leukemia & Lymphoma Society of Canada’s results and impact.
Charity Intelligence has not yet rated Leukemia & Lymphoma Society of Canada on impact (n/r).
My anchor
Finances
In F2023 Leukemia & Lymphoma Society of Canada received $15.0m in cash donations. Administrative costs are 16% of revenues (excluding investment income). Fundraising costs are 28% of donations. This results in total overhead spending of 44%. For every dollar donated, 56 cents go to the cause. This falls outside Ci’s reasonable range for overhead spending. LLSC has been outside this range for almost every year of Ci’s analysis.
In F2023 LLSC spent $9.1m on its programs and grants, which is 58% of its revenue. In F2023 it had a surplus of $27k.
Leukemia & Lymphoma Society of Canada has $14.3m in reserve funds, of which $260k is donor endowed. Excluding donor-endowed funds, this can cover 154%, or one year and six months of its annual program spending. LLSC has total investments of $7.0m. 59% is in equities, 27% in bonds and 14% in alternative investments. In F2023 the annual return on investment for LLSC was 9%. Its five-year annual return on investment is 6%.
In F2023, LLSC paid external fundraisers $560k who collected $1.9m in donations. This means it cost LLSC 30 cents to raise $1 using external fundraisers.
This charity report is an update that has been sent to Leukemia & Lymphoma Society of Canada for review. Changes and edits may be forthcoming.
Updated on June 11, 2024, by Grady Simpson.
Financial Review
Fiscal year ending June
|
2023 | 2022 | 2021 |
|---|---|---|---|
| Administrative costs as % of revenues | 16.0% | 13.5% | 12.6% |
| Fundraising costs as % of donations | 28.4% | 26.2% | 26.6% |
| Total overhead spending | 44.4% | 39.7% | 39.2% |
| Program cost coverage (%) | 154.2% | 155.9% | 197.8% |
Summary Financial StatementsAll figures in $000s |
2023 | 2022 | 2021 |
|---|---|---|---|
| Donations | 14,955 | 15,590 | 12,996 |
| Government funding | 0 | 144 | 777 |
| Investment income | 814 | (443) | 1,157 |
| Other income | 0 | 0 | 4 |
| Total revenues | 15,769 | 15,291 | 14,933 |
| Program costs | 5,419 | 5,047 | 4,372 |
| Grants | 3,683 | 3,735 | 2,859 |
| Administrative costs | 2,393 | 2,128 | 1,737 |
| Fundraising costs | 4,247 | 4,082 | 3,451 |
| Total spending | 15,742 | 14,993 | 12,419 |
| Cash flow from operations | 27 | 299 | 2,515 |
| Capital spending | 146 | 124 | 315 |
| Funding reserves | 14,280 | 13,930 | 14,537 |
Note: DEFERRED ADJUSTMENT: LLSC uses deferred accounting. To show donors information on a consistent basis, Ci adjusted for these deferred revenues. This affected revenues by ($84k) in F2023, ($454k) in F2022, and $404k in F2021. RESEARCH EXPENSES: The audited financial statements report direct research expenses and allocated research expenses. Ci reports direct research expenses as grants and allocated research expenses as program costs. DIRECT EVENT FUNDRAISING EXPENSES: The audited financial statements include direct event fundraising costs as a reduction in revenue. Ci has made adjustments to include this cost in fundraising expenses. As a result, both revenues and expenses increased by $463k in F2023, $445k in F2022, and $262k in F2021. INVESTMENT MANAGEMENT FEES: Ci removed investment management fees. This affected revenues by ($49k) in F2023, ($46k) in F2022, and ($41k) in F2021. AMORTIZATION: Ci removed amortization of capital assets on a pro-rata basis from program, administrative and fundraising costs. GRANTS AND FELLOWSHIPS PAYABLE: Ci adjusted grants based on the change to Grants and Fellowship payable year over year. This affected total expenses by ($1.1m) in F2023, ($1.4m) in F2022, and $1.7m in F2021.
Salary Information
$350k + |
0 |
$300k - $350k |
0 |
$250k - $300k |
0 |
$200k - $250k |
0 |
$160k - $200k |
1 |
$120k - $160k |
5 |
$80k - $120k |
4 |
$40k - $80k |
0 |
< $40k |
0 |
Information from most recent CRA Charities Directorate filings for F2023
My anchor
Comments & Contact
Comments added by the Charity:
Below are comments added by the charity for a past profile. New comments made by the charity for this updated profile may be forthcoming:
The Leukemia & Lymphoma Society of Canada (LLSC) expanded its mission in 2005 to include patient education, support and programs in addition to the research projects that had been funded since our inception in 1955. This effort, which included the addition of Social Workers and/or Oncology Nurses to support patients to our staff team, has gradually spread out across Canada and continues to grow to this present day. At the same time, it was decided that LLSC should increase its geographical reach outside of Vancouver, Calgary and Toronto so we could offer support coast-to-coast. In the last few years, we have added in stages staffed offices in Montreal, Edmonton, Saskatoon, Ottawa, Quebec City and Halifax (as of January, 2011) to meet this mandate. LLSC has also made a concerted effort to provide all materials and programming in both official languages, which were previously only available in English. These projects involve large expenditures up front, but were deemed crucial to our ability to properly meet our mission across Canada. We are proud LLSC is now truly a national organization that can help Canadians coast-to-coast through their journey with blood cancer and also give them hope for a healthy future by funding top-notch research.
Charity Contact
This email address is being protected from spambots. You need JavaScript enabled to view it. Tel: 1-833-222-4884